Last Updated: October 2, 2026

CLINICAL TRIALS PROFILE FOR SEMAXANIB

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for Semaxanib

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00003720 ↗	SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma	Completed	Pfizer	Phase 1	RATIONALE: SU5416 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating patients who have AIDS-related Kaposi's sarcoma.
NCT00004252 ↗	Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer	Completed	Pfizer	Phase 3	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor. It is not yet known whether chemotherapy is more effective with or without SU5416 in treating metastatic colorectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of leucovorin and fluorouracil with or without SU5416 in treating patients who have metastatic colorectal cancer.
NCT00004868 ↗	SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	RATIONALE: SU5416 may stop the growth of astrocytoma or glioma by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of SU5416 in treating patients who have recurrent astrocytoma or mixed glioma that has not responded to previous radiation therapy.
NCT00004868 ↗	SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy	Completed	North American Brain Tumor Consortium	Phase 1/Phase 2	RATIONALE: SU5416 may stop the growth of astrocytoma or glioma by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of SU5416 in treating patients who have recurrent astrocytoma or mixed glioma that has not responded to previous radiation therapy.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for Semaxanib

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Sarcoma	5
Unspecified Adult Solid Tumor, Protocol Specific	4
Colorectal Cancer	3
Head and Neck Cancer	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Sarcoma	5
Colorectal Neoplasms	3
Neoplasms	2
Central Nervous System Neoplasms	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Semaxanib

Trials by Country

Map
Table

Trials by Country
Location	Trials
United States	147
Canada	14
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
California	11
Texas	9
Illinois	7
New York	7
Ohio	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Semaxanib

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	12
Phase 1/Phase 2	5
[disabled in preview]	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	21
Terminated	4
Unknown status	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Semaxanib

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
National Cancer Institute (NCI)	25
Case Comprehensive Cancer Center	3
Radiation Therapy Oncology Group	2
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
NIH	25
Other	18
Industry	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.